Isthmus Partners LLC Trims Stock Holdings in OmniAb, Inc. (NASDAQ:OABI)

Isthmus Partners LLC lessened its position in shares of OmniAb, Inc. (NASDAQ:OABI) by 15.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 446,134 shares of the company’s stock after selling 82,251 shares during the period. Isthmus Partners LLC’s holdings in OmniAb were worth $1,887,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Atria Investments Inc bought a new position in OmniAb during the 3rd quarter worth approximately $148,000. Rice Hall James & Associates LLC lifted its holdings in OmniAb by 6.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after buying an additional 163,038 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in OmniAb during the 2nd quarter worth approximately $147,000. Sei Investments Co. lifted its holdings in OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after buying an additional 2,888 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after buying an additional 194,835 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb Trading Up 3.2 %

Shares of OmniAb stock opened at $3.90 on Friday. The business’s 50 day simple moving average is $4.10 and its 200-day simple moving average is $4.23. The stock has a market capitalization of $550.76 million, a price-to-earnings ratio of -6.29 and a beta of -0.12. OmniAb, Inc. has a twelve month low of $3.56 and a twelve month high of $6.72.

Analyst Ratings Changes

A number of research firms have commented on OABI. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 target price on shares of OmniAb in a report on Friday, August 16th. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th. Finally, Benchmark reiterated a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.